GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Shiller PE Ratio

Atara Biotherapeutics (STU:AT2) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Atara Biotherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atara Biotherapeutics Shiller PE Ratio Historical Data

The historical data trend for Atara Biotherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Shiller PE Ratio Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atara Biotherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Atara Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Shiller PE Ratio falls into.



Atara Biotherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Atara Biotherapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Atara Biotherapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.212/131.7762*131.7762
=-0.212

Current CPI (Mar. 2024) = 131.7762.

Atara Biotherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.171 100.560 -0.224
201409 -0.237 100.428 -0.311
201412 -0.543 99.070 -0.722
201503 -0.388 99.621 -0.513
201506 -0.552 100.684 -0.722
201509 -0.383 100.392 -0.503
201512 -0.689 99.792 -0.910
201603 -0.521 100.470 -0.683
201606 -0.587 101.688 -0.761
201609 -0.784 101.861 -1.014
201612 -0.597 101.863 -0.772
201703 -0.823 102.862 -1.054
201706 -0.837 103.349 -1.067
201709 -0.856 104.136 -1.083
201712 -0.972 104.011 -1.231
201803 -0.852 105.290 -1.066
201806 -0.984 106.317 -1.220
201809 -1.106 106.507 -1.368
201812 -1.538 105.998 -1.912
201903 -1.274 107.251 -1.565
201906 -1.416 108.070 -1.727
201909 -1.189 108.329 -1.446
201912 -1.224 108.420 -1.488
202003 -1.086 108.902 -1.314
202006 -1.012 108.767 -1.226
202009 -0.781 109.815 -0.937
202012 -0.781 109.897 -0.936
202103 -0.722 111.754 -0.851
202106 -0.755 114.631 -0.868
202109 -0.765 115.734 -0.871
202112 -0.850 117.630 -0.952
202203 -0.790 121.301 -0.858
202206 0.170 125.017 0.179
202209 -0.828 125.227 -0.871
202212 -0.680 125.222 -0.716
202303 -0.672 127.348 -0.695
202306 -0.628 128.729 -0.643
202309 -0.618 129.860 -0.627
202312 -0.514 129.419 -0.523
202403 -0.212 131.776 -0.212

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atara Biotherapeutics  (STU:AT2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Atara Biotherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (STU:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (STU:AT2) Headlines

No Headlines